| # | Drug | Count |
|---|---|---|
| 0 | OXALIPLATIN | 14 |
| 1 | ETOPOSIDE | 11 |
| 2 | IMATINIB | 11 |
| 3 | FLUOROURACIL | 10 |
| 4 | FLUOROURACIL CREAM, 0.5% | 10 |
| 5 | DOCETAXEL | 8 |
| 6 | DOCETAXEL ANHYDROUS | 8 |
| 7 | CISPLATIN | 7 |
| 8 | CARBOPLATIN | 6 |
| 9 | IFOSFAMIDE | 6 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | LAROTRECTINIB | 1 | 0.0011 |
| 1 | ETHIODIZED OIL | 1 | 0.0008 |
| 2 | ESTROGEN | 2 | 0.0007 |
| 3 | BREXUCABTAGENE AUTOLEUCEL | 1 | 0.0005 |
| 4 | BLEOMYCIN SULFATE | 4 | 0.0004 |
| 5 | INOTUZUMAB OZOGAMICIN | 1 | 0.0003 |
| 6 | VINORELBINE | 2 | 0.0003 |
| 7 | IFOSFAMIDE FOR INJECTION | 6 | 0.0003 |
| 8 | ERLOTINIB HYDROCHLORIDE | 3 | 0.0002 |
| 9 | BICALUTAMIDE | 3 | 0.0002 |
| # | Drug class | Count |
|---|---|---|
| 0 | Platinum-based Drug [EPC] | 25 |
| 1 | Nucleoside Metabolic Inhibitor [EPC] | 11 |
| 2 | Topoisomerase Inhibitor [EPC] | 11 |
| 3 | Alkylating Drug [EPC] | 9 |
| 4 | Microtubule Inhibitor [EPC] | 9 |
| 5 | Androgen Receptor Inhibitor [EPC] | 3 |
| 6 | Estrogen [EPC] | 2 |
| 7 | Kinase Inhibitor [EPC] | 2 |
| 8 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 2 |
| 9 | BCL-2 Inhibitor [EPC] | 1 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD22-directed Immunoconjugate [EPC] | 1 | 0.0003 |
| 1 | Topoisomerase Inhibitor [EPC] | 11 | 0.0001 |
| 2 | Platinum-based Drug [EPC] | 25 | 0.0001 |
| 3 | Microtubule Inhibitor [EPC] | 9 | 0.0001 |
| 4 | Programmed Death Ligand-1 Blocker [EPC] | 1 | 0.0000 |
| 5 | Androgen Receptor Inhibitor [EPC] | 3 | 0.0000 |
| 6 | Nucleoside Metabolic Inhibitor [EPC] | 11 | 0.0000 |
| 7 | Radiographic Contrast Agent [EPC] | 1 | 0.0000 |
| 8 | Alkylating Drug [EPC] | 9 | 0.0000 |
| 9 | BCL-2 Inhibitor [EPC] | 1 | 0.0000 |